viewAgenus Inc

Agenus soars on collaboration with Incyte, seen as "major validation"

Shares of Agenus (NASDAQ:AGEN) rocketed more than 30 percent today after the company announced a co-development collaboration with Incyte (NASDAQ:INCY) to develop immuno-oncology antibodies.


Shares of Agenus (NASDAQ:AGEN) rocketed more than 30 percent today after the company announced a co-development collaboration with Incyte (NASDAQ:INCY) to develop immuno-oncology antibodies.

The alliance will initially focus on four different checkpoint modulator targets directed against GITR, OX40, LAG-3 and TIM-3. 

The two parties will share all costs and profits for the GITR and OX40 antibody programs evenly, according to a joint statement released earlier today. TIM-3 and LAG-3 are royalty-bearing programs which will be funded by Incyte

Agenus will receive $60 million upfront, with the potential for $350 million in milestones tied to the development and commercialization of the antibodies against the four targets.

The development program will use Agenus' proprietary Retrocyte Display antibody discovery platform, which was acquired by the company last year. First clinical trials are expected to begin next year.

H.C. Wainwright analyst Reni Benjamin reiterated the capital markets firm's buy rating on Agenus' stock and 12-month price target of $6. Shares surged 30.7 percent to US$5.37 in New York on Friday, stretching gains over the past year to more than 76 percent.

"In our opinion, the partnership is excellent news for investors as it represents a second major validation for the company's investment in Agenus' platform technology, which has already attracted a collaboration with Merck," Benjamin wrote in his research note released this afternoon.

"Given the resources at Incyte, we believe the new agreement should accelerate the clinical development of new checkpoint antibodies, as well as provide considerable financial flexibility, leaving Agenus free to pursue additional opportunities surrounding the unpartnered PD-1 and CTLA-4 programs."

HCW said that with about $106.4 million in cash, the potential to secure new partnerships and a "highly versatile" platform, it believes Agenus remains an undervalued player in the immuno-oncology space.

The HCW analyst also noted that the collaboration also leaves room for joint development of additional checkpoint modulators. Benjamin calculates that if Agenus chooses a profit-sharing route for future targets, it could receive up to $20 million in milestones per program.

"Given Incyte's experience with successful development of ruxolitinib, we are particularly excited about the potential synergy that could be achieved by deploying new checkpoint modulators in combination with Incyte's small molecule portfolio," said Benjamin.

Quick facts: Agenus Inc

Price: 3.79 USD

Market: NASDAQ
Market Cap: $520.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Sativa Group signs significant product listing with WH Smith...

Sativa Group (Nex: SATI) CEO Henry Lees-Buckley dropped into the Vancouver studio of Proactive with news the company has signed a major CBD product listing agreement with WH Smith Travel.  Lees-Buckley talks about just how big that deal is and what he has been hearing from customers...

9 hours, 49 minutes ago

3 min read